Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM)

被引：5
|
作者：
Nowak, A. K. [1 ]
Millward, M. J. [1 ]
Francis, R. [1 ]
van der Schaaf, A. [1 ]
Musk, A. W. [1 ]
Byrne, M. J. [1 ]
机构：
[1] Sir Charles Gairdner Hosp, Perth, WA, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.8063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8063
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II trial of gefitinib in patients with malignant pleural mesothelioma (MPM)
    Lee, C. W.
    Anderson, H.
    Martins, H.
    Rao, S. C.
    Sauciuc, D.
    Laurie, S. A.
    Morzycki, W.
    MacNeil, M. V.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] A Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM)
    Wozniak, A.
    Schneider, B.
    Kalemkerian, G.
    Daly, R.
    Chen, W.
    Ventimiglia, J.
    Nagasaka, M.
    Zauderer, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S343 - S343
  • [33] Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)
    Castagneto, B.
    Botta, M.
    Aitini, E.
    Spigno, F.
    Degiovanni, D.
    Alabiso, O.
    Serra, M.
    Muzio, A.
    Carbone, R.
    Buosi, R.
    Galbusera, V.
    Piccolini, E.
    Giaretto, L.
    Rebella, L.
    Mencoboni, M.
    ANNALS OF ONCOLOGY, 2008, 19 (02) : 370 - 373
  • [34] Carboplatin and Gemcitabine chemotherapy for malignant pleural mesothelioma (MPM): A phase II study of the GSTPV
    Aversa, SML
    Arcuri, C
    De Pangher, V
    Favaretto, A
    Endrizzi, L
    Sartore, F
    Giunta, G
    Toso, S
    Biasion, R
    Paccagnella, A
    ANNALS OF ONCOLOGY, 1998, 9 : 117 - 117
  • [35] Pemetrexed second-line treatment in malignant pleural mesothelioma (MPM) following platinum-based first-line treatment
    Sorensen, Jens B.
    Sundstrom, Stein
    Perell, Katharina
    Thielsen, Anne-Kathrine
    ANNALS OF ONCOLOGY, 2006, 17 : 216 - 216
  • [36] PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB PLUS PEMETREXED AND CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM)
    Ceresoli, Giovanni L.
    Zucali, Paolo A.
    Favaretto, Adolfo G.
    De Vincenzo, Fabio
    Mencoboni, Manlio
    Botta, Mario
    Grossi, Francesco
    Bidoli, Paolo
    Zilembo, N.
    Simonelli, Matteo
    Gianoncelli, Letizia
    Lorenzi, Elena
    Santoro, Armando
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S538 - S539
  • [37] Treatment with gemcitabine and vinorelbine (GEMVIN) as second-line chemotherapy in pemetrexed-pretreated patients with malignant pleural mesothelioma (MPM)
    Garassino, Isabella
    Ceresoli, Giovanni L.
    De Vincenzo, Fabio
    Zucali, Paolo A.
    Cavina, Raffaele
    Campagnoli, Elisabetta
    Salamina, Silvia
    Parra, Hector J. Soto
    Santoro, Armando
    ANNALS OF ONCOLOGY, 2006, 17 : 231 - 231
  • [38] Vinflunine (VFL) in first line treatment of malignant pleural mesothelioma (MPM):: Final results of a European phase II study
    Margery, J.
    Dabouis, G.
    Dark, G.
    Taylor, H.
    Pinel, M. C.
    Cadic, V.
    Ruffle, P.
    Talbot, D.
    LUNG CANCER, 2006, 54 : S47 - S47
  • [39] Evaluation of second line treatment of malignant pleural mesothelioma (MPM) at a large teaching hospital
    Williams, C.
    Appleton, E.
    Clarke, K.
    Franks, K.
    Snee, M.
    Jain, P.
    LUNG CANCER, 2020, 139 : S72 - S72
  • [40] Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
    Zhang, Dandan
    Liang, Jianping
    Lv, Yanhua
    Huang, Xikun
    Guo, Weihong
    MEDICINE, 2022, 101 (52) : E32459
12345